| City: |
|
La Crosse |
|
State:
|
|
WI |
| Zip Code: |
|
54601 |
| Conditions: |
|
Metastatic Cancer - Prostate Cancer |
| Purpose: |
|
RATIONALE: Drugs used in chemotherapy, such as docetaxel, prednisone, and atrasentan work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor
cells. It is not yet known whether docetaxel, prednisone, and atrasentan are more effective
than docetaxel and prednisone in treating prostate cancer.
PURPOSE: This randomized phase III trial is studying docetaxel, prednisone, and atrasentan
to see how well they work compared to docetaxel and prednisone in treating patients with
stage IV prostate cancer and bone metastases that did not respond to previous hormone
therapy.
|
| Study summary: |
|
OBJECTIVES:
Primary
- Compare the survival and progression-free survival of patients with hormone-refractory
stage IV prostate cancer and bone metastases treated with docetaxel and prednisone
combined with either atrasentan vs placebo.
Secondary
- Compare pain progression of patients treated with these regimens.
- Compare the qualitative and quantitative toxicity of these regimens in these patients.
- Compare the quality of life, in terms of palliation of metastatic bone pain and
improvement in functional status, of patients treated with these regimens.
- Compare prostate-specific antigen (PSA) response rates in patients treated with these
regimens.
- Compare objective response in patients with measurable disease treated with these
regimens.
- Determine whether a 30% reduction in PSA and the slope of PSA from baseline to 3 months
is a surrogate marker for survival in patients treated with these regimens.
- Correlate PSA progression with clinical progression and death in patients treated with
these regimens.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
are stratified according to disease progression (measurable or non-measurable disease
progression vs prostate-specific antigen progression only), use of bisphosphonates at study
entry (yes vs no), worst pain, measured by the Brief Pain Inventory "pain" scale (< grade 4
vs ≥ grade 4), and extraskeletal metastases (yes vs no). Patients are randomized to 1 of 2
treatment arms.
- Arm I: Patients receive docetaxel IV over 1 hour on day 1. Patients also receive oral
atrasentan and oral prednisone once daily on days 1-21. Treatment repeats every 21 days
for up to 12 courses. Patients with stable or responding disease after course 12 may
register for continued oral atrasentan treatment for up to 52 weeks in the absence of
disease progression* or unacceptable toxicity.
- Arm II: Patients receive docetaxel and prednisone as in arm I. Patients also receive
oral placebo once daily on days 1-21. Treatment repeat every 21 days for up to 12
courses. Patients with stable or responding disease after course 12 may register for
continued oral placebo treatment for up to 52 weeks in the absence of disease
progression* or unacceptable toxicity.
NOTE: *Patients with PSA progression alone will be allowed to continue treatment
Quality of life is assessed at baseline, before courses 4, 7, and 10, and then after
completion of study treatment.
After completion of study treatment, patients are followed every 3 months for 1 year and
then every 6 months for up to 3 years from study entry.
PROJECTED ACCRUAL: A total of 930 patients will be accrued for this study within 4 years. |
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the prostate
- Stage IV disease (any T, any N, M1b)
- Evidence of bone metastases by bone scan or MRI
- Measurable or nonmeasurable disease
- Soft tissue disease that has been irradiated within the past 2 months is not
assessable as measurable disease
- Hormone-refractory disease despite androgen deprivation and antiandrogen withdrawal,
as defined by 1 of the following criteria:
- Prostate-specific antigen (PSA) progression, defined as 3 consecutive rising PSA
levels* taken ≥ 1 week apart
- PSA ≥ 5 ng/mL NOTE: *If the third confirmatory PSA level is < the second
level, the patient is considered eligible provided a fourth PSA level is >
the second level
- Progression of measurable disease
- Progression of nonmeasurable disease by bone scan
- Must have undergone surgical or medical (e.g., luteinizing hormone-releasing hormone
[LHRH] agonist [e.g., leuprolide or goserelin] or LHRH antagonist therapy) castration
- Patients who have undergone medical castration must continue LHRH agonist or
antagonist therapy during study treatment
- Must have completed 12 courses of blinding protocol treatment (atrasentan/placebo)
AND stopped docetaxel for any reason (including completion of 12 courses) other than
progressive disease
- No symptomatic pleural effusion
- No third space fluid accumulation (e.g., ascites)
- No prior or concurrent brain metastases
- Patients with clinical evidence of brain metastases must have a negative brain
CT scan or MRI within the past 8 weeks
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Zubrod 0-3* NOTE: For a performance status of 3, the cause must be due to pain
secondary to bone metastases
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Fertile patients must use effective contraception
- Able to take oral medication without crushing, dissolving, or chewing tablets
- No major infection
- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer or stage I or II cancer in complete remission
- No symptomatic sensory neuropathy ≥ grade 2
- No history of hypersensitivity reaction to docetaxel or other drugs formulated with
polysorbate 80
- No other significant, active medical illness that would preclude study treatment or
survival
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No more than 1 prior systemic vaccine or biologic therapy
- At least 4 weeks since prior vaccine or biologic therapy and recovered
- No concurrent biological response modifiers
- No concurrent prophylactic colony-stimulating factors
Chemotherapy
- More than 2 years since prior adjuvant therapy with a single non-taxane-containing
cytotoxic regimen
- No prior cytotoxic chemotherapy for metastatic prostate cancer
- No other concurrent chemotherapy
Endocrine therapy
- See Disease Characteristics
- At least 6 weeks since prior bicalutamide or nilutamide AND has subsequent disease
progression
- At least 4 weeks since prior flutamide or ketoconazole AND has subsequent disease
progression
- Prior or concurrent megestrol for treatment of hot flashes allowed
- No other concurrent corticosteroid or hormonal therapy unless continuing luteinizing
hormone-releasing hormone treatment and/or bisphosphonate therapy
Radiotherapy
- See Disease Characteristics
- Prior samarium allowed
- At least 3 weeks since prior radiotherapy and recovered
- No prior radiotherapy to ≥ 30% of the bone marrow
- No prior strontium
- No concurrent radiotherapy
Surgery
- See Disease Characteristics
- At least 3 weeks since prior surgery and recovered
Other
- More than 4 weeks since prior investigational drugs
- Concurrent bisphosphonates allowed provided therapy is started prior to study entry,
dose is maintained during the first 12 weeks of study treatment, and patient meets
criteria for disease progression
- No initiation of bisphosphonates during the first 12 weeks of study treatment
- No concurrent herbal medications or food supplements (e.g., PC-SPES, saw palmetto,
Hypericum perforatum [St. John's wort])
- Concurrent daily vitamins and calcium supplements allowed
- At least 14 days since prior and no concurrent administration of any of the
following:
- Antibiotics (e.g., clarithromycin, erythromycin, troleandomycin, rifampin,
rifabutin, and rifapentine)
- Antifungals (e.g., itraconazole, ketoconazole, fluconazole [doses > 200 mg/day],
and voriconazole)
- Antidepressants (e.g., nefazodone and fluovoxamine)
- Calcium channel blockers (e.g., verapamil, diltiazem)
- Miscellaneous (e.g., amiodarone [no use within 6 months prior to study entry],
grapefruit juice, bitter orange, or modafinil)
- Anticonvulsants (e.g., phenytoin, carbamazepine, phenobarbital, and
oxcarbazepine)
- Antibiotics (e.g., rifampin, rifabutin, and rifapentine) |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|